Peter-Huber-Cropped

Noted author, attorney Peter Huber spoke at Clemson April 12

Rick Uhlmann, College of Business and Behavioral Science March 22, 2016 Peter Huber, senior fellow at the Manhattan Institute for More »

Hudson.Talk.TWH.12.8.15

A Century of Spectrum Overregulation and the Quest to Liberate Wireless Technologies

via Hudson Institute With the FCC’s relentless drive to regulate new technologies, a look back at the history of the More »

Skinner

Nationally recognized health-care economist, Jonathan Skinner spoke at Clemson University on Nov. 4

November 4, 2015 Jonathan Skinner, a nationally recognized health-care economist, spoke Nov. 4 at Clemson University on the U.S. health care More »

Time for the Supremes to Decide ‘Net Neutrality’

rcm_logo_followTime for the Supremes to Decide ‘Net Neutrality’

By Thomas Hazlett & Joshua Wright

The FCC’s dramatic 2015 pivot on Internet regulation sought to envelope advanced broadband networks in the shroud of telephone company rules rolled out in the Mann Elkins Act of 1910. These historic common carriage “Title II” regulations – originally the province of the Interstate Commerce Commission, long ago antiquated and finally abolished in 1995 — were cited as exemplars by the Commission in last year’s Open Internet Order.

Important decision on Net Neutrality

The D.C. Circuit Court of Appeals has released its important decision on Net Neutrality rules adopted by the FCC.  The case, USTA v. FCC, features multiple citations to the academic work of Professor Thomas Hazlett.  See the June 14, 2016 opinion here.

The Hill: Patients dying because of FDA inflexibility

Thinkstock

Patients dying because of FDA inflexibility

By Thomas W. Hazlett – 05/25/16 05:08 PM EDT
via The Hill

 

On May 26, the Food and Drug Administration will decide whether to approve eteplirsen, a therapy for Duchenne multiple dystrophy (DMD), on a fast-track basis. The drug, made by Sarepta Therapeutics, is the first for this brutal disease, which strikes about 500 boys annually in the U.S. It shows up before the age of five, putting kids in wheelchairs by their teens and ending tragically in premature death. An advisory panel in April voted against approval of the medicine, 7-6. At the hearing, parents of boys afflicted by DMD became hysterical. They pleaded for the majority to reverse course and let their children try the medication.